TICASPAN TABLET

💊🛡️ Ticagrelor 90mg Tablet: Fast-Acting Antiplatelet for Heart Attack & Stroke Prevention

Ticagrelor 90mg is a prescription antiplatelet medication used to reduce the risk of heart attacks, strokes, and cardiovascular death in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). Belonging to the class of P2Y12 receptor antagonists, Ticagrelor prevents platelet aggregation—a key step in blood clot formation—thereby protecting patients at risk of dangerous arterial blockages.

It is most commonly prescribed alongside low-dose aspirin as part of dual antiplatelet therapy (DAPT) after a heart attack, stent placement, or unstable angina.

🔬 Mechanism of Action

Ticagrelor selectively and reversibly inhibits the P2Y12 ADP receptor on the platelet surface. This prevents:

• Platelet activation

• Platelet aggregation

• Thrombus (clot) formation in arteries

Unlike clopidogrel (which is a prodrug and irreversible), Ticagrelor:

• Works directly and reversibly

• Has a faster onset of action

• Does not require metabolic activation, giving more predictable effects

This makes it especially beneficial in urgent cardiac care scenarios.

📌 Indications and Uses

Ticagrelor 90mg tablets are used for:

• Acute Coronary Syndrome (ACS):

  • Unstable angina

  • Non-ST Elevation Myocardial Infarction (NSTEMI)

  • ST-Elevation Myocardial Infarction (STEMI)

• Post-percutaneous coronary intervention (PCI) with stent placement

• Secondary prevention of atherothrombotic events in patients with a history of MI

• Often used for up to 12 months post-MI, followed by 60mg dose for long-term therapy

💊 Dosage and Administration

• Standard dose: 90mg twice daily, with low-dose aspirin (75–100mg once daily)

• Should be taken at the same time every day, with or without food

• Not to be used with high-dose aspirin (>100mg daily), as it may reduce Ticagrelor’s effectiveness

• Tablets should be swallowed whole, not crushed unless prescribed

⚠️ Precautions and Warnings

• Contraindicated in:

  • Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)

  • Severe liver impairment

  • History of intracranial hemorrhage

• Caution in:

  • Patients with asthma or COPD (may cause dyspnea)

  • Bradycardia or heart block

  • Use alongside other anticoagulants or NSAIDs (increased bleeding risk)

Regular monitoring may include:

• Bleeding risk assessment

• Hemoglobin and hematocrit levels

• Renal and liver function

🤒 Side Effects

Common:

• Bleeding (nosebleeds, bruising, GI bleeding)

• Shortness of breath (dyspnea)

• Headache

• Nausea

Serious:

• Major or fatal bleeding

• Ventricular pauses (especially during the first week)

• Allergic reactions

Seek immediate medical help for uncontrolled bleeding, black stools, blood in vomit, or fainting.

🔄 Drug Interactions

• Avoid strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)

• Avoid CYP3A4 inducers (e.g., rifampin, phenytoin)

• Use cautiously with digoxin and statins (especially simvastatin >40mg)

🧊 Storage Instructions

• Store at 20–25°C

• Protect from moisture and light

• Keep out of reach of children

📝 Conclusion

Ticagrelor 90mg is a potent, fast-acting antiplatelet that significantly lowers the risk of recurrent heart attacks and strokes in high-risk cardiac patients. Its reversible inhibition, rapid onset, and proven mortality benefit make it a key component of modern post-ACS care. With proper use and monitoring, it provides life-saving protection against thrombotic events.